BACK
TO MAIN
PAGE

Clostridioides difficile infection (CDI)

General Information

Clostridioides difficile (C. difficile) is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals.

Currently, no vaccine is licensed for the prevention of CDI.

Transmission

The transmission of C. difficile can be patient-to-patient, via contaminated hands of healthcare workers or by environmental contamination.

Symptoms

Clostridioides difficile (C. difficile) is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals. The clinical spectrum of C. difficile infection (CDI) ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis. 

Show More

Epidemiology

1 in 11 people over age 65 diagnosed with a healthcare-associated C. difficile infection die within one month.

The number of deaths occurring as the direct consequence of healthcare-associated CDI can be estimated at 3,700 per year in the EU/EEA.

The burden of healthcare-associated CDIs in acute care hospitals in the EU/EEA was estimated at 123,997 cases annually. 

Vaccines
Pipeline

3
Vaccines in
the pipeline

Technology Platforms

  • Protein subunit​ (2)
  • Toxoid vaccine (1)

DEVELOPMENT PHASES

  • Phase I (1)
  • Phase II (1)
  • Phase III (1)

TRIAL POPULATION

    Adults + Older Adults (2)​
    Older Adults (1)​

Sources: 
https://www.ecdc.europa.eu/en/clostridium-difficile-infections/facts
https://www.cdc.gov/cdiff/what-is.html

[Accessed: November 2022]

Vaccines Europe Pipeline Review

Download our pipeline review